06. July 2021 | 11:34 CET
Bayer, XPhyto Therapeutics, Pfizer: Here comes the blockbuster of the 4th wave
Hygiene sluices, rapid tests, disinfectants and vaccines - what was more familiar to laboratory staff or doctors a few years ago has become our daily bread since the outbreak of the pandemic. It stands to reason that the new normality would also leave its mark on the stock market. Indeed, the shares of major pharmaceutical companies have already risen. However, there are still newcomers with considerable potential. Growth companies, in particular, could benefit from the hype surrounding hygiene and health.
time to read:
ISIN: BAYER AG NA O.N. | DE000BAY0017 , XPHYTO THERAPEUTICS | CA98421R1055 , PFIZER INC. DL-_05 | US7170811035
Bayer: Value - and what else?
Bayer is anything but a growth company. Nevertheless, the Leverkusen-based Company is currently regarded by many stock market experts as an exciting pick. Why? The Company is the market leader, shines with good figures and has largely shaken off the glyphosate dispute, which has been a burden for many years, at least in its share price. Added to this is a dividend that currently convinces many investors with more than a 5% dividend yield. While Bayer offers no hope of being the next multiplier, a hefty dividend is a good argument, especially for risk-averse investors.
In addition to its health care offerings, Bayer also operates in the agricultural technology sector, benefiting from rising commodity prices and the improving inflationary environment. The stock is not hot, but it is a solid one. Over a year, the stock has returned more than 20%. There is not so much fantasy in Bayer at the moment, but there is a lot of value.
XPhyto: Next-generation PCR test comes to Berlin
On the other hand, the young Canadian Company XPhyto Therapeutics, which does business in Germany and elsewhere, is more on the growth path. XPhyto has developed a method that enables PCR tests to deliver meaningful results within 20-25 minutes. After only a little more time than error-prone antigen tests, XPhyto's solution provides PCR-quality certainty. Airports or hotels, in particular, could take advantage of the offer. Given the upcoming wave of travel, XPhyto's solution could strike a nerve.
The Company signed an agreement with ten test centers at the end of June and sent the first tests to Berlin. In addition to test kits, XPhyto offers solutions to help the human body better absorb medical agents, such as patches and solutions, and is developing drugs. In addition to a neurological drug, the Canadians are also working with psychedelic agents. The stock has been on a dive for weeks. While this may not attract investors at first glance, XPhyto Therapeutics offers an exciting product mix. The PCR tests could become a bread-and-butter business in a quarter-wave, and the activities around psychoactive compounds spark the imagination. Investors can bookmark XPhyto - the list of potential catalysts for a turnaround is long.
Pfizer: What can the Corona profiteer do?
While fantasy lurks in XPhyto, Pfizer's stock is an open book: the Company is one of the largest pharmaceutical companies in the world, making a name for itself primarily with several blockbuster drugs, each of which generates more than USD 1 billion in annual sales. Pfizer also benefits from its collaboration with BioNTech on the Covid-19 vaccine. Still, the stock has not really gotten off the ground in the past year - the price tags show a yield of just 9%. In addition, there is a dividend of around 3.5% measured against the current share price. The Pfizer share will no longer be a high-flyer but can be a solid foundation in a conservative portfolio.
Nevertheless, for private investors especially, it can make sense to invest a little more speculatively in the pharmaceutical, laboratory diagnostics, and biotech sectors. While relevant returns on Pfizer and Bayer can only be achieved with large position sizes, courageous speculators can profit with small investments in XPhyto Therapeutics. The rapid PCR test with results from 20 minutes could become the blockbuster of the fourth wave. Given a market capitalization of less than EUR 100 million, the share price is likely to react more clearly to such a development than it would to a big player like Pfizer and Co.